Generic placeholder image

Current Diabetes Reviews

Eiditor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Pegaptanib Sodium for the Treatment of Proliferative Diabetic Retinopathy and Diabetic Macular Edema

Author(s): Gian P. Giuliari, David A. Guel and Victor H. Gonzalez

Volume 5 , Issue 1 , 2009

Page: [33 - 38] Pages: 6

DOI: 10.2174/157339909787314158

Price: $58

Abstract

Diabetes mellitus is a growing health concern world-wide. Patients with this disease present with a variety of health conditions, including a number of sight-threatening ocular pathologies. Proliferative diabetic retinopathy (PDR) and diabetic macula edema (DME) are common diseases that cause substantial vision impairment in diabetic patients. There has been a strong focus on studying the epidemiology and treatment of these diseases. The recent discovery of vascular endothelial growth factor (VEGF) and its role in the development of proliferative disease, has led to a movement towards treating PDR and DME with anti-angiogenic medications in conjunction with the standard of care. In this review we present a summary of the origination and progression of PDR and DME. This will be followed by a review of clinical data surrounding new anti-angiogenic treatment modalities.

Keywords: Pegaptanib sodium (Macugen), Proliferative diabetic retinopathy, Diabetic macular edema, Diabetes mellitus


Article Metrics
13
Related Journals
Related eBooks
Related Articles
© 2019 Bentham Science Publishers